Iaso Private General Obstetrics Gynecological & Pediatric Clinic Diagnostic Therapeutic & Research Center S.A. — Clinical Trial Site

15 Registered trials

10 Currently recruiting

Organisation

Iaso Private General Obstetrics Gynecological & Pediatric Clinic Diagnostic Therapeutic & Research Center S.A.

Location

Filothei, Greece

Identifier

ORG-100046574

Address

Kifissias Leoforos 37-39, 151 23, Greece

Departments

1st Oncology Clinic
2nd Medical Oncology Department
2nd Oncology Clinic
3rd Medical Oncology Department
3rd Oncology Clinic
4th Oncology Clinic
A' Oncology Clinic
Department of Pediatric Neurology
Neurological Department of Pediatric Clinic
Obstetrics - Gynecology Clinic, B’ Oncology Clinic
Obstetrics-Gynecology Clinic B΄Oncology Clinic
Oncology

Clinical trials at this site (15)

Search interface

Trial of T-DXd Versus SoC Chemotherapy as Adjuvant Treatment in Endometrial Cancer Recruiting

2024-519444-33-00 HER2-expressing endometrial cancer (IHC 3+/2+) 5 2026-03-12
A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting

2023-507525-42-00 Endometrial cancer 5 2025-12-23
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A Study to compare RLY-2608 + Fulvestrant with Capivasertib + Fulvestrant in people with PIK3CA-mutated, hormone-receptor positive, HER2-neg… Recruiting

2025-523083-21-00 PIK3CA-mutant Hormone Receptor Positive, Human Epiderma 5 2025-12-08
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 pMMR endometrial carcinoma 5 2025-08-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can… Recruiting

2023-507914-28-00 Platinum-resistant, high-grade serous ovarian cancer (O 10 2024-06-19
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally 5 2023-10-12
A clinical study to evaluate safety and efficacy of Caribasmate Ended

2023-506616-41-00 Lennox-Gastaut syndrome (LGS) 5 2023-03-31
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscu… Ended

2024-511492-15-00 Duchenne Muscular Dystrophy 5 2021-12-09
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Pa… Ended

2023-508489-14-00 Solid Tumors 4 2023-09-18